Which countries run stem-cell trials for Stroke Recovery?
Sites appear in 22 countries, led by China at about 31% of all country mentions (2026-08-29).
Country distribution
| Country | Studies with a site there |
|---|---|
| China | 28 |
| United States | 24 |
| Taiwan | 8 |
| India | 8 |
| United Kingdom | 5 |
| France | 5 |
| Spain | 4 |
| South Korea | 4 |
| Malaysia | 3 |
| United Arab Emirates | 2 |
A study with sites in several countries is counted once per country, taken from the location block of each registry record.
What the map means for Stroke Recovery
Registrations follow stroke units with imaging and standardised outcome scoring. Rehabilitation intensity varies enormously between countries, and it is a stronger determinant of recovery than any cell product currently on offer.
Where recruitment is actually open
| Country | Open studies with a site there |
|---|---|
| China | 3 |
| United Arab Emirates | 1 |
| United States | 1 |
| South Korea | 1 |
| Indonesia | 1 |
| Japan | 1 |
| Antigua and Barbuda | 1 |
| Argentina | 1 |
What travelling for a trial actually involves
Travelling to a trial site is not like booking a treatment package. Sites enrol people they can follow up, which usually means repeated visits over months, local imaging or bloods, and an emergency route if something goes wrong. Ask about all three before booking anything.
Multi-country studies, named
Registered studies with sites in more than one country — the clearest evidence of collaboration rather than a single-centre series.
- NCT05158101 — Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosome Intranasal Instillations for St (Antigua and Barbuda, Argentina)
Why trial geography is not a shortlist
Where studies happen reflects who funds and who authorises them. Treating that as a ranking of care quality confuses the research system with the treatment market, two things that overlap far less than medical-tourism marketing implies.
Before treating geography as a shortlist, read the legality overview by country and what "best country" actually means here.
When these studies started
Registrations by start year since 2020: 2020 (4), 2021 (6), 2022 (4), 2023 (4), 2024 (4), 2025 (7), 2026 (8), 2027 (1). Activity for this condition spans 2005 to 2027, which shows whether interest is growing, flat or past its peak.
Frequently asked
Which countries run stem-cell trials for Stroke Recovery?
Sites are registered in 22 countries; the largest is China (~31% of country mentions, 2026-08-29).
Does a country with many trials mean better treatment there?
It does not follow. A country can host many trials and still have an unregulated commercial sector selling something quite different to visitors.
Are trial sites and commercial clinics the same thing?
Rarely. Academic trial sites and the private clinics advertising to medical tourists are typically separate organisations with different oversight.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Stroke Recovery: cell-therapy evidence and registered trials
- How much does stem cell therapy for Stroke Recovery cost? (2026)
- Stroke Recovery stem cell therapy — your questions answered (2026)
- Stroke Recovery: cell-therapy evidence by therapy class
- MSC vs HSCT for Stroke Recovery: what the registries show